Colorectal Cancer
Colorectal Cancer
Advertisement
Olatunji B. Alese, MDBile Duct Cancer | July 25, 2025
Dr Alese discusses the importance of addressing health disparities among younger and minority populations and more.
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti highlights 100% response with PD-1 blockade in dMMR rectal cancer and new chemoimmunotherapy for anal cancer.
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti shares BREAKWATER, CheckMate 8HW, and CHALLENGE results improving metastatic colorectal cancer outcomes.
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti highlights ATOMIC as the new standard for stage III dMMR colon cancer and compares it to the NICHE approach.
Christopher Lieu, MDEsophageal Cancer | July 16, 2025
Dr. Lieu lists and describes DESTINY-Gastric04, CHALLENGE, MATTERHORN, BREAKWATER, and ATOMIC.
Leah LawrenceColorectal Cancer | July 16, 2025
KRAS mutations drive GI cancers, but new inhibitors, vaccines, and combinations are advancing efforts to target them.
Scott Kopetz, MD, PhDColorectal Cancer | July 10, 2025
Dr. Kopetz explains how BREAKWATER aligns with Project FrontRunner to support accelerated approval in BRAF V600E-mutated CRC.
Benjamin Weinberg, MD, FACPColorectal Cancer | June 30, 2025
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Jessica GangaColorectal Cancer | June 27, 2025
Findings from the CheckMate 8HW trial highlight a potential shift in treatment strategy for patients with MSI-H/dMMR mCRC.
Emily MenendezColorectal Cancer | June 24, 2025
A three-year structured exercise program provided significantly longer DFS for patients with colon cancer.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel concludes with an in-depth discussion on the evolving role of ctDNA in colorectal cancer management.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel highlights the BREAKWATER study and explores practical considerations for therapy before biomarker results.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel discusses strategies for IO in CRC, including the ATOMIC trial and adoption of neoadjuvant checkpoint inhibition.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel explores the evolving treatment landscape for patients with MSI-high metastatic colorectal cancer.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel dives into the role of biomarker testing in CRC, noting how next-gen sequencing and MSI testing are essential.
Erica Barnell, MD, PhDColorectal Cancer | June 18, 2025
Dr. Barnell discusses ColoSense's NCCN Guidelines inclusion for CRC and how it impacts the cancer screening landscape.
Benjamin Weinberg, MD, FACPColorectal Cancer | June 10, 2025
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Jeanne Tie, MD, MBChBASCO 2025 | June 6, 2025
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Christopher Lieu, MDColorectal Cancer | June 5, 2025
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
Lauren Dembeck, PhDColorectal Cancer | June 5, 2025
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
Advertisement